The Klein Law Firm Reminds Investors of Class Actions on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
60
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ORA, REPH, FLR, FIZZ, NWL and PCG

NEW YORK, July 23, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.       

Ormat Technologies, Inc. (NYSE: ORA ) Class Period: August 8, 2017 to May 15, 2018 Lead Plaintiff Deadline: August 8, 2018

The lawsuit alleges that throughout the class period, Ormat Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were errors in the income tax provision primarily relating to Ormat’s valuation allowance based on its ability to utilize foreign tax credits in the U.S. prior to their expiration; (2) Ormat netted certain deferred income tax assets and deferred income tax liabilities across different tax jurisdictions that are not permitted to be netted pursuant to United States generally accepted accounting principles; (3) Ormat’s internal controls over financial reporting were ineffective; (4) Ormat would need to restate its second, third and fourth quarter 2017 financial statements and its full-year 2017 financial statements; and (5) as a result, defendants’ statements about Ormat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.   

Get additional information about the ORA lawsuit: http://www.kleinstocklaw.com/pslra-c/ormat-te...c-2?wire=3 .

Recro Pharma, Inc. (NASDAQ: REPH ) Lead Plaintiff Deadline: July 30, 2018 Class Period: July 31, 2017 - May 23, 2018

Allegations: (1) the Company's lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration ("FDA") approval; and (2) as a result, Recro Pharma's public statements were materially false and misleading at all relevant times.

Get additional information: http://www.kleinstocklaw.com/pslra-c/recro-ph...c-2?wire=3 .

Fluor Corporation (NYSE: FLR ) Class Period: August 14, 2013 to May 3, 2018 Lead Plaintiff Deadline: July 24, 2018

During the class period, Fluor Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fluor’s bidding process for projects related to the construction of gas-fired power generation facilities was flawed; (ii) Fluor had improperly estimated the gas-fire projects; (iii) as a result, Fluor would face craft productivity issues, equipment issues and other execution issues; (iv) Fluor would incur multiple charges impacting quarterly results; and (v) Fluor would ultimately decide to discontinue the pursuit of the gas-fired power market.

Get additional information about the FLR lawsuit: http://www.kleinstocklaw.com/pslra-c/fluor-co...ion?wire=3 .

National Beverage Corp.  (NASDAQ: FIZZ ) Class Period: July 17, 2014 to July 3, 2018 Lead Plaintiff Deadline: September 17, 2018

According to the complaint, National Beverage Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) National Beverage's sales claims and its supposed "proprietary techniques" lacked a verifiable basis; (2) the Company's Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage's public statements were materially false and misleading at all relevant times. On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).”  National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage's CEO had sexually harassed them. 

Get additional information about the FIZZ lawsuit: http://www.kleinstocklaw.com/pslra-c/national...orp?wire=3 .

Newell Brands Inc. (NYSE: NWL ) Class Period: February 6, 2017 to January 24, 2018 Lead Plaintiff Deadline: August 20, 2018

During the class period, Newell Brands Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s retail channel was loaded with extremely high levels of unsold Newell product; (ii) contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; (iii) as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and (iv) undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance.

Get additional information about the NWL lawsuit: http://www.kleinstocklaw.com/pslra-c/newell-b...inc?wire=3 .

P&GE Corporation (NYSE: PCG ) Class Period: April 29, 2015 to June 8, 2018 Lead Plaintiff Deadline: August 13, 2018

The lawsuit alleges P&GE Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, PG&E was in violation of state law regulation; (iii) PG&E’s electricity networks would cause numerous wildfires in California; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business and operations were materially false and misleading at all relevant times.

Get additional information about the PCG lawsuit: http://www.kleinstocklaw.com/pslra-c/pge-corporation?wire=3 .

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Center Transformers on the Brink of a Boom

Updated Category News Views 272

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Continue Reading
Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 50

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
Essity's SEK 850m Bet: Expanding Lilla Edet Facility

Updated Category News Views 99

Essity Doubling Down on Hygiene Hygiene is something you can't compromise on, and Essity gets that. They're shelling out a cool SEK 850 million into their production facility at Lilla Edet in Sweden—no small change, even in the grand scheme of corporate investment. Why the Massive Investment? It's not just about throwing money around; this move is strategic. Essity’s...

Continue Reading
OI Investors Crack Down: Class Action Filing Looms

Updated Category News Views 183

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 24

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Eve Air Mobility's Vector System Proves Its Worth

Updated Category News Views 84

Eve Air Mobility's Vector system just pulled off something impressive at the Interlagos Circuit, showing it's not just a buzzword in the urban air mobility sphere. Picture this—over 100 helicopter flights in a day, all managed smoothly during one of the biggest motorsport events. That's the kind of action that gets investors to sit up and take notice of NYSE:EVEX....

Continue Reading
NueSynergy Secures Top Spot in HSA Provider Rankings

Updated Category News Views 107

NueSynergy Earns its Stripes in 2026 It seems these days, healthcare costs are rising faster than you can say 'deductible.' In this chaotic landscape, a good HSA provider is worth its weight in gold. Enter NueSynergy, whose efforts have once again been acknowledged by Morningstar, a big name in the world of investment research. What Sets NueSynergy Apart? NueSynergy isn't...

Continue Reading
SciGround Launches: A Game-Changer in Research Verification

Updated Category News Views 148

Unshackling Research Verification from the Model Folks, here's the big one—Licklider, Inc. from Tokyo lobbed a curveball with their new player in town: SciGround. This platform takes the reins on mathematically verifying AI-driven research, which is something you'll want to keep an eye on if you're at all interested in AI or research replication. Why SciGround Gets My...

Continue Reading
JardogsHealth Taps Industry Titans for Growth Council

Updated Category News Views 99

JardogsHealth: A New Chapter with Strategic Insights You've got to admire when a company rounds up a top-tier brain trust. Such is the case with JardogsHealth, the healthcare AI outfit nestled in Hillsboro, Illinois, as they align their future alongside heavyweights who’ve maneuvered through multiple industries and come out thriving. Their brand-new council includes...

Continue Reading
Dahua's Pro Challenge 2026: Bridging Expertise Globally

Updated Category News Views 90

Celebrating Global Installer Expertise Dahua Technology took to the stage in Hangzhou for the Pro Challenge 2026, a shindig pulling installer partners from every corner of the globe. This wasn't just a tech jamboree; it was a tip of the hat to those on the ground who make Dahua's AIoT solutions tick. You know the drill: hands-on demos, tech showcases, and a whole lot of...

Continue Reading

Top 5 Most Recently Viewed Articles

AI’s Dual Nature: Growth Potential or Path to Collapse?

Updated Category News Views 242

The Dichotomy of AI: Catalyst for Growth or Collapse? Yes, AI is a catalyst, though what it catalyzes remains uncertain. The prevailing narrative suggests that our foremost challenge is the need for affordable energy to support the burgeoning data centers of AI technology. Fortunately, solutions are emerging, including the construction of modular nuclear power plants and...

Continue Reading
Ponche Kuba Refreshes Its Look While Keeping Original Flavor

Updated Category News Views 280

Exciting New Look for Ponche Kuba Today marks an exciting chapter in the world of liqueurs as Ponche Kuba unveils its new packaging design, an evolution of its iconic Caribbean rum cream liqueur. Since its inception in 1942 by Don Jaime A. J. Sprock, Ponche Kuba has maintained a loyal following due to its unique flavor and quality. Although the aesthetic has transformed,...

Continue Reading
Unlocking Crypto Success: Double Bonuses and 100x Leverage

Updated Category News Views 129

BexBack Introduces Exciting Crypto Trading Offers BexBack is revolutionizing the cryptocurrency trading landscape with dynamic offers designed for traders looking to capitalize on recent market volatility. Following significant developments in the industry, BexBack has stepped up to provide traders with exceptional options, making it easier than ever to start trading....

Continue Reading
Innovative Partnership Between eMolecules and Optic for Drug Discovery

Updated Category News Views 75

Transforming Drug Discovery with AI Collaboration In an exciting development for the pharmaceutical industry, eMolecules, a leading chemical sourcing company, has joined forces with Optic, a digital biology firm. This collaboration aims to revolutionize the drug discovery process by leveraging the power of artificial intelligence. Together, these companies are creating a...

Continue Reading
Vivani Medical Advances Canine Health with Expanded Collaboration

Updated Category News Views 214

Collaborative Efforts to Enhance Canine Metabolic Health Vivani Medical, Inc. and Okava Pharmaceuticals, Inc. have announced an exciting expansion of their partnership, aiming to enhance the metabolic health and longevity of dogs. With a mutual vision for veterinary medicine, the collaboration focuses on the development of OKV-119, a long-acting GLP-1 therapy designated...

Continue Reading